Systemic hormonal and physiological abnormalities in anxiety disorders

Psychoneuroendocrinology

Volumn 13, Issue 4, 1988, Pages 287-307

  Cameron, Oliver G ^a   Nesse, Randolph M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL GLAND; ANXIETY; CONTROLLED STUDY; GONAD; HUMAN; HUMAN EXPERIMENT; HYPOPHYSIS; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOPHYSIOLOGY; REVIEW; THYROID GLAND;

ANIMAL; ANXIETY DISORDERS; AROUSAL; BRAIN; HORMONES; HUMAN; NEUROTRANSMITTERS;

EID: 0023783506     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4530(88)90054-6     Document Type: Review

References (239)

1. Cortisol and growth hormone responses to psychological stress during the menstrual cycle
2. The relationship between anxiety and the level of peripheral vasomotor activity
3. Interactions of stress, salt, and blood pressure
4. Self-report and physiologic responding during an vivo flooding
5. Biochemical indices of lactate induced panic: a preliminary report
6. The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder
7. Stress hormones: their interaction and regulation
8. A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic levels to treatment response
9. Platelet serotonin levels in panic disorder
10. Patterns of desynchrony in agoraphobia: a preliminary report
11. Unexplained breathlessness and psychiatric morbidity in patients with normal and abnormal coronary arteries
12. Emotional influences on breathing and breathlessness
13. Physiological and psychological measures in anxious patients
14. Metabolic studies in mitral valve prolapse syndrome: a neuroendocrine-cardiovascular process
15. Mitral valve prolapse syndrome: the effect of adrenergic stimulation
16. Anxiety
17. Cardiovascular control by cholinergic mechanisms in the central nervous system
18. Dexamethasone suppression test in patients with panic attacks
19. Arrhythmias documented by 24-hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease
20. Influence of exercise on anxiety level in patients with anxiety disorders
21. 2-adrenergic receptor binding and plasma catecholamines
22. Obsessive-compulsive disorder and the DST
23. Symptom profiles of patients with DSM-III anxiety disorders
24. Endocrine and physiological changes during “spontaneous” panic attacks
25. Symptoms of insulin-induced hypoglycemia in normal subjects
26. Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy
27. Noradrenergic function and the mechanisms of action of antianxiety treatment: I. The effect of long-term alprazolam treatment
28. Noradrenergic function and the mechanism of action of antianxiety treatment: II. The effect of long-term imipramine treatment
29. Abnormal regulation of noradrenergic function in panic disorders
30. Serotonin function in panic disorders
31. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine
32. Noradrenergic function in panic anxiety
33. Increased anxiogenic effects of caffeine in panic disorders
34. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks
35. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects
36. Habituation of physiological responses in anxiety
37. Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness
38. Phobia questionnaire responses and urine catecholamines
39. A cognitive approach to panic
40. Adrenergic hyperactivity and cardiac abnormality in primary disorders of sleep
41. Dysautonomia in mitral valve prolapse
42. Life situations, emotions, and neurocirculatory asthenia (anxiety neurosis, neurasthenia, effort syndrome)
43. β-adrenergic blockers and buspirone
44. Diagnosis and treatment of the hyperventilation syndrome
45. The influence of sodium amytal on the respiratory abnormalities of anxious psychiatric patients
46. Lactate infusion: the role of baseline anxiety
47. Mitral valve prolapse and panic disorder
48. Exercise and anxiety neurosis
49. The sympathoadrenal system in human glucose counterregulation and diabetes mellitus
50. Psychoendocrine stress response: Steroid and peptide hormones
51. Fainting on exposure to phobic stimuli
52. Anxiety and plasma cortisol at the crest of the circadian cycle: reappraisal of a classical hypothesis
53. Plasma growth hormone: effect of anxiety during flooding in vivo
54. The dexamethasone suppression test in panic disorder and agoraphobia
55. “Flooding in vivo” during the circadian phase of minimal cortisol secretion: anxiety and therapeutic success without adrenal cortical activation
56. Differentiation of anxious patients by two dimensional echocardiographic evaluation of the mitral valve
57. Mitral valve prolapse in a psychiatric setting: diagnostic assessment, research and clinical implications
58. Mitral valve abnormalities and catecholamine activity in anxious patients
59. A comparison of inpatients with primary unipolar depression and depression secondary to anxiety
60. Biological stress responses in high and low trait anxious students
61. Mitral valve prolapse and borderline hypertension
62. Autonomic reactions to social and neutral stimuli in subjects high and low in public speaking fear
63. Severe anxiety induced by FG 7142, a betacarboline ligand for benzodiazepine receptors
64. Buspirone: review of its pharmacology and current perspectives on its mechanism of action
65. Regulatory role of gamma-aminobutyric acid in pituitary hormone secretion
66. Plasma serotonin levels in agoraphobia
67. Behavior and circulatory catecholamines
68. Cortisol excretion during the defense reaction in humans
69. Psychophysiological factors in panic disorder
70. Ambulatory monitoring of panic disorder
71. Serum dopamine-β-hydroxylase activity in depression and anxiety
72. The physiological and pharmacological control of anterior pituitary hormone secretion
73. Autonomic dysfunction in women with mitral valve prolapse syndrome
74. Abnormal cardiovascular regulation in the mitral valve prolapse syndrome
75. Neurophysiology and neuropharmacology of cardiovascular regulation and stress
76. Effect of pregnancy on panic attacks
77. Anxiety states: relationship to atmospheric cations and serotonin
78. Physiologic responses in anxious women patients. A study of autonomic activity and muscle tension
79. The magnitude of premenstrual anxiety and depression
80. Response to hyperventilation in a group of patients with panic disorder
81. Insulin levels during lactate infusion
82. Platelet monoamine oxidase activity in patients with panic disorder
83. Blood gas changes and hypophosphatemia in lactate-induced panic
84. Prevalence of mitral valve prolapse in panic disorder: effect of echocardiographic criteria
85. Synchronous and desynchronous changes during fear reduction
86. Prolactin response to the cold pressor test in patients with panic attacks
87. Plasma glucose and lactic acid alterations in response to a stressful exam
88. Urinary excretion of noradrenaline metabolite decreased in panic disorder
89. Forearm blood flow in normal subjects and patients with phobic anxiety states
90. Cardiovascular response to stress in man
91. Neurotransmitters in anxiety
92. Effects of naloxone on normals and chronically anxious patients
93. Generalized anxiety disorder
94. Effects of clonidine on anxiety disorders
95. Blood lactate concentration in relation to absolute and relative work load in normal men, and in mitral stenosis, atrial systolic defect, and vasoregulatory asthenia
96. Emotion and blood pressure
97. Naloxone administration in obsessive-compulsive disorder: report of two cases
98. A Comparison of the Exercise Response in Anxiety States and Normal Controls
99. The biological basis of anxiety: an overview
100. The electrocardiogram in neurocirculatory asthenia (anxiety, neurosis or neurasthenia). A study of 203 neurocirculatory asthenia patients and 757 healthy controls in the Framingham study
101. Hyperthyroidism and panic attacks
102. Depression and anxiety associated with hyperthyroidism: response to antithyroid therapy
103. Measurement of anxiety by forearm blood flow
104. A clinical and physiological relationship between anxiety and depression
105. Platelet MAO-B activity in anxiety and depression
106. Panic induced elevation of plasma MHPG levels in phobic-anxious patients
107. Palmar skin conductance measures in anxiety and phobic states
108. Assessment methods and the differential diagnosis of anxiety
109. Biological differentiation of anxiety, arousal, and stress
110. Physiological changes during spontaneous panic attacks
111. Anxiety and mood fluctuation during the normal menstrual cycle
112. Physiological and subjective measures of anxiety during flooding
113. A psychophysiological analysis of fear modification using an automated desensitization procedure
114. Anxiety and caffeine consumption in people with anxiety disorders
115. Studies in neurocirculatory asthenia (DaCosta's syndrome). I. Variations with regard to symptoms and some pathophysiological signs
116. The prevalence of mitral valve prolapse in patients with panic disorders
117. Dexamethasone suppression tests in patients with panic disorder
118. Clonidine treatment of panic disorder
119. Effects of naloxone on patients with panic attacks
120. Lactate provocation of panic attacks. II. Biochemical and physiological findings
121. Propranolol increases reduced beta-receptor function in severely anxious patients
122. Thyroid dysfunction in phobic patients
123. Hyperventilation: the tip and the iceberg
124. The syndrome of habitual chronic hyperventilation
125. Relationships between central nervous system noradrenergic function and plasma and urinary MHPG and other norepinephrine metabolites
126. Hyperventilation syndromes: infrequently recognized common expressions of anxiety and stress
127. Hypothalamic control of autonomic functions
128. Screening for thalassaemia and/or iron deficiency: Evaluation of some discrimination functions
129. Pharmacological responsiveness of sweat glands in anxious patients and healty volunteers
130. Basic and clinical aspects of adenosinergic neuromodulation
131. Corticosteroid responses to hospital admission
132. Hematocrit and anxiety
133. Anxiety and serum prolactin
134. Catechol-0-methyltransferase and catecholamines in anxiety and relaxation
135. Acetylcholinesterase and pseudocholinesterase activities in anxiety
136. MAO, DBH, and COMT: the effect of anxiety
137. Catecholamines and monoamine oxidase activity in anxiety
138. Catecholamines and dopamine-β-hydroxylase in anxiety
139. Catecholamines and anxiety
140. Mitral valve prolapse and thyroid abnormalities in patients with panic attacks
141. The pineal hormone melatonin in panic disorder
142. Stress and thyroid function
143. Somatic symptoms of anxiety: comparison of self-report and physiological measures
144. Hyperventilation syndrome
145. Growth hormone and cortisol responses to psychological stress: comparison of normal and neurotic subjects
146. The relationship between psychological and physiological measures of anxiety
147. Urinary 3′5′-cyclic adenosine monophosphate (cAMP) as a measure of anxiety
148. Anxiety induced by flooding therapy for phobias does not elicit prolactin secretory response
149. Phobic anxiety does not affect plasma levels of thyroid stimulating hormone in man
150. Adrenergic function in patients with panic anxiety
151. Endocrine and cardiovascular responses during phobic anxiety
152. Urinary catecholamines and mitral valve prolapse in panic anxiety patients
153. Platelet serotonin uptake in panic disorder
154. Beta-adrenergic blocking drugs in anxiety and stress
155. 2-adrenoreceptor sensitivity in panic disorder
156. Platelet binding studies in panic disorder
157. Plasma cyclic nucleotide responses to psychological stress in normal and neurotic subjects
158. Electrodermal psychophysiology of anxiety disorder: orienting response and spontaneous fluctuations
159. Physiological responses in blood phobics
160. Increased plasma catecholamine levels in patients with symptomatic mitral valve prolapse
161. The benzodiazepine-GABA-chloride ionophore receptor complex: common site of minor tranquilizer action
162. The biochemistry of anxiety: from pharmacotherapy to pathophysiology
163. Plasma catecholamines at rest and exercise in subjects with high- and low-trait anxiety
164. Adrenal Cortical Function in Anxious Human Subjects
165. 11C]-labelled R015-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography
166. The dexamethasone suppression test in agoraphobia
167. Some physiologic antecedents of adult mental health
168. Plasma MHPG levels in lactate and isoproterenol anxiety states
169. Sources of variance in clinical studies of MHPG
170. QT interval prolongation and increased plasma catecholamine levels in patients with mitral valve prolapse
171. Norepinephrine challenges in panic attacks
172. Sweating and its disorders
173. Cardiac arrhythmias in the monkey during classically conditional fear and excitement
174. Decreased skin conductance response habituation in chronically anxious patients
175. New and old evidence for the involvement of a brain norepinephrine system in anxiety
176. Neuroendocrinology
177. Benzodiazepines: use and misuse
178. Benzodiazepine receptors in “emotional” and “non-emotional” mice: comparison of four strains
179. Endocrine responses to stressful psychological events
180. Urinary free cortisol levels in anxiety
181. Autonomic characteristics of agoraphobia with panic attacks
182. Panic disorder and major depression: biological relationships
183. Neuroendocrine abnormalities in panic disorder
184. Plasma HVA and anxiety in patients with anxiety disorder
185. The corticotropin-releasing hormone stimulation test in patients with panic disorder
186. Premenstrual syndromes: overview from a methodologic perspective
187. SYMPTOMS OF ANXIETY AND TENSION AND THE ACCOMPANYING PHYSIOLOGICAL CHANGES IN THE MUSCULAR SYSTEM
188. The effects of benzodiazepine and non-benzodiazepine anxiolytics on locus coeruleus unit activity
189. Buspirone, a non-benzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity
190. 3H] imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks
191. The dexamethasone suppression test in generalized anxiety disorder
192. Insulin-induced hypoglycemia and panic attacks
193. Pathophysiology of panic: a review of pharmacologic provocative tests and naturalistic monitoring data
194. Cardiac rate and rhythm in panic patients
195. Some Biochemical Correlates of Panic Attacks with Agoraphobia and Their Response to a New Treatment
196. Panic attacks and the dexamethasone suppression test
197. Catechol-0-methyl transferase activity in patients with depressive illness and anxiety states
198. Central neural integration for the control of autonomic responses associated with emotion
199. Behavioral and molecular actions of caffeine: focus on adenosine
200. Arrhythmias documented by 24-hour continuous ambulatory electrocardiographic monitoring in young women without apparent heart disease
201. Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: putative implications for psychiatry and psychopharmacology
202. Physiological correlates of anxiety: a preliminary investigation of the orienting reflex
203. Ambulatory heart rate changes during panic attacks
204. Ambulatory heart rate changes in patients with panic attacks
205. The effect of phobic anxiety on plasma β-endorphin: a single-subject experiment
206. Neurotransmitter regulation of anterior pituitary hormones
207. Central and peripheral correlates of anxiety: a comparative study
208. Awareness of cardiac function in anxious, phobic, and hypochondriacal patients
209. The relationship of plasma free MHPG to anxiety and psychophysical pain in normal volunteers
210. Caffeine: relationship to human anxiety, plasma MHPG, and cortisol
211. Glucose tolerance testing in panic disorder
212. Phenomenology and neurobiology of panic disorder
213. Blunted growth hormone response to clonidine in panic disorder patients
214. 3H] imipramine binding in patients with panic disorder
215. Plasma β-endorphin, pain thresholds and anxiety levels across the human menstrual cycle
216. Behavioral stress and cardiac arrhythmias
217. Sympathetic nervous system activity in panic disorder
218. Neurocirculatory asthenia (anxiety neurosis, effort syndrome, neurasthenia): a twenty year follow-up of one hundred and seventy-three patients
219. Physiological effects of performing a difficult task in patients with anxiety states
220. Carbon Dioxide Sensitivity in Panic Anxiety
221. Situational panic attacks
222. Resting plasma catecholamine concentrations in patients with depression and anxiety
223. Preinfusion anxiety predicts lactate-induced panic attacks in normal controls
224. Comparison of biochemical properties of platelet monoamine oxidase in mentally disordered and healthy individuals
225. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology